Connect with us

News

Why living in an almshouse could lead to a longer, happier life

Published

on

Almhouses have been providing charitable shelter to the elderly in the UK since medieval times.

The world’s oldest form of social housing. more than 1,000 years after they first opened their doors, they are still providing a place to live to over 36,000 mainly older residents in almost 2,600 almhouses across Britain. The sizes of these communities vary from a few dozen to several hundred residents.

The low-cost, self-sufficient community housing schemes aimed at local people in need are a singular success story.

But almshouses may be doing more than just providing a much-needed roof over the head for those in need.

A new study suggests living in an almshouse can boost the longevity of its residents by as much as two-and-a-half years compared to their counterparts in the general population.

The report from the Bayes Business School found that a 73-year-old male moving into an almshouse today, such as the Tudor-era Charterhouse in London, could expect to live an extra 15% of future lifetime at the point of joining compared to his peers from the same socioeconomic group who lived elsewhere.

When compared to others of the same age, residents of the best-performing almshouses in the study who are in the lowest socio-economic quintile were found to have the same life expectancy as the wealthiest 40% in society.

The Almshouse Longevity Study builds on a 2017 report that looked at life expectancy in Whiteley Village in Surrey, a purpose-built retirement community set in 225 acres opened during World War One, that showed the average resident lived longer in the almshouse-style cottages than the typical citizen in England and Wales of the same age, gender and socioeconomic background.

It was this report that prompted the Almshouse Association – the support organisation representing over 1,600 independent almshouse charities across the UK – to do a follow-up study to look at whether this effect could be seen across this particular social housing movement more generally.

Fifteen almshouses around the UK that primarily house men, women or couples of state pension age, were examined for this latest research, including Charterhouse, the Durham Aged Mineworkers Homes Association, the Royal Hospital Chelsea in central London – home of the iconic Chelsea Pensioners in their long scarlet coats and tricorne hats – Salisbury City Almshouse, and Trinity Hospital in West Retford, Nottinghamshire.

In a foreword to the report, the chief executive of the Almshouse Association, Nick Phillips, suggests this latest research “builds on past research pointing, perhaps, to the great value of companionship and strong micro-communities that this unique housing model embodies.

“I would like to suggest that, if we were to design a housing model which is the epitome of a good living environment today, it would include companionship, community and independent living in almshouses which are designed to underpin these values.”

This community spirit is reflected in the architectural design of traditional almshouses – often a three-sided quadrangle with doors and windows facing each other over a courtyard or community area – enabling a sense of togetherness and companionship, yet still allowing independence.

These design features are still commonly replicated in almshouses being built today.

They are run by charities and residents pay rent which is generally cheaper than that being charged by councils, housing associations or private landlords for local property.

Analysing up to 100 years’ worth of residents’ records from the various almshouses in England, this latest research suggests that living in these communities can reduce the negative impact on health and social wellbeing which is commonly experienced by the older population in lower socioeconomic groups, particularly those individuals who are living in isolation.

It shows that the disparity in longevity and health outcomes could be mitigated even after reaching retirement age, provided a suitable social infrastructure can be put in place.

Professor Ben Rickayzen, professor of Actuarial Science at Bayes Business School, and a co-author of the report, said: “It is well known that, on average, the lower a person’s socioeconomic status, the lower their life expectancy.

“However, intriguingly, our research has found that this doesn’t have to be  the case. We discovered that many almshouse residents receive a longevity boost when compared to their peers of the same socioeconomic status from the wider population.

“More research is needed to ascertain exactly what factors cause almshouse residents to have a longer life; however, we postulate that it is the sense of the community that is the most powerful ingredient.

“For example, a common theme within the almshouses included in the study is that they encourage residents to undertake social activities and responsibilities on behalf of their fellow residents. This is likely to increase their sense of belonging and give them a greater sense of purpose in their everyday lives while mitigating against social isolation.

“We would encourage the Government to invest in retirement communities, such as almshouses, which would be in keeping with their overarching levelling up agenda.

“While this agenda is commonly associated with enhancing equality on a regional basis, it is important that levelling up should also aim to combat health inequalities experienced by people from lower socioeconomic groups across the country.

“There is an opportunity to improve the Government’s levelling up agenda by incorporating the best features of communal living into their social housing policy. This should make a significant difference to the quality of life experienced by the older population across the UK.

“The findings from this research are important as they could offer solutions to the social care problems currently being experienced in the UK.”

The authors of the report, sponsored by the Dunhill Medical Trust and the Justham Trust, and supported by the Almshouse Association, write that two of the best-performing almshouses, Charterhouse and Morden College, both in London, “have a very focused centre physically as they are both based in one or two main buildings, and also communally as, for example, Charterhouse and Morden College both have community dining rooms where residents can eat and socialise together.

“We speculate that this strong sense of community and interaction is combatting the loneliness ‘epidemic’ that previous research has identified as being especially prominent among older age groups, with those aged 70-79 most affected by social isolation.”

The authors added: “If we consider all the almshouses that participated in the study, a common theme is that they have all created a strong sense of community. We believe that this is one of the major contributors to the boost in life expectancy of almshouse residents when compared to similar people from the same socio-economic groupings.”

The authors acknowledge that further research is needed to “determine a full outline of the factors that may be contributing to the longevity boost.”. They also admit that almshouse living may not suit everyone, and that it wouldn’t provide an automatic boost in longevity to all.

“The social interaction that we believe could be a significant reason why living in an almshouse might boost longevity will only work if residents enjoy this type of environment,” the authors write.

Alison Benzimra, a co-author of the report and head of research at United St Saviour’s Charity, which supports the people and communities of north Southwark in London, said: “Many almshouse trustees and staff members anecdotally believe that almshouse living is beneficial for residents.

“The results from this study demonstrate that the community spirit provided by almshouses does in fact result in longer life expectancy.

“These findings are encouraging to those living and working in the almshouse community and provide the motivation to continue to explore what it is about almshouses’ physical design and support services that result in positive outcomes for older residents.

“This study strengthens the case that this historic form of housing is addressing the evolving needs of older people living in our modern-day society.”

News

Longevity startup Biopeak secures US$2.7m

Published

on

Longevity startup Biopeak has secured US$2.7m in a follow-on round led by NKSquared, the investment vehicle of Zerodha co-founder Nikhil Kamath.

This is Kamath’s second investment in the company after he put US$1.43m into the health optimisation startup in August 2024.

Founded in 2025 by Rishi Pardal and Shiva Subramanian, Biopeak operates India’s first specialised brand aimed at extending lifespans through preventive care.

It opened a clinic in Bengaluru last year and plans to open a second in the coming month.

The funds will be used to expand Biopeak’s operations, including the new clinic and enhancements to its diagnostics, proprietary artificial intelligence (AI) tools, research initiatives and clinical programmes, Pardal told ET. The startup also plans to hire for its clinical, research, product and operations teams while strengthening ties with global advisers for protocol development.

ET reported in June that the wellness and longevity startup raised US$3m in seed funding from Claypond Capital, the family office of Manipal Group chairman Ranjan Pai, Accel India cofounder Prashanth Prakash and existing investor Rainmatter, the investment arm of Zerodha.

Pardal said: “Since our last fundraise, we conclusively proved we can attract clients and deliver outcomes.

“Around August, we started our second flagship store while building capabilities in new diagnostic tests and AI-driven diagnosis for personalised programmes.

“All this requires investment to further validate product-market fit and scale our systems.”

Biopeak targets high achievers, executives and women, relying on programmes mixing advanced diagnostics, specialist teams, wearable data and AI insights tailored to Indian biology and disease patterns.

The model stresses early risk detection, longitudinal tracking and interventions to improve performance and resilience.

Over the past year, Biopeak has grown its client base and clinical offerings amid rising demand for structured longevity services.

Pardal said consumer attitudes towards proactive health are changing in India, but integrated systems linking diagnostics and follow-up remain scarce.

“Longevity and well-being interest is exploding across newspapers, social circles and web searches. People have intent and awareness.” the chief executive added.

The longevity sector is gaining momentum in the country as rising incomes and health awareness drive demand for preventive care beyond traditional episodic treatments.

With life expectancy surpassing 72 years but healthy life expectancy not catching up, such startups are tapping into a market projected to grow in the coming years on the back of India’s ageing population.

Continue Reading

News

Study reveals link between cheese and dementia

Published

on

A 25-year Swedish study links higher cheese intake to lower Alzheimer’s risk in people without known genetic risk, with cream also tied to lower dementia risk.

However, researchers emphasise that the results should be interpreted with caution.

The study tracked 27,670 people over 25 years.

During that time, 3,208 participants were diagnosed with dementia.

Among individuals without a known genetic risk for Alzheimer’s disease, those who consumed more than 50 grams of full-fat cheese per day showed a 13 to 17 per cent lower risk of developing Alzheimer’s.

This association did not appear in participants who carried genetic risk factors for the disease.

People who consumed more than 20 grams of full-fat cream per day also showed a lower risk of dementia overall, ranging from 16 to 24 per cent.

No meaningful links were found for low-fat or high-fat milk, fermented or non-fermented milk, or low-fat cream.

The results stand out because public health guidance has long encouraged people to choose low-fat dairy to protect heart health.

This connection matters because cardiovascular disease (conditions affecting the heart and blood vessels) and dementia share many underlying risk factors, including high blood pressure, diabetes and obesity.

When evidence from previous studies is combined, analyses suggest that cheese consumption may also be linked to a lower risk of heart disease, and that full-fat dairy does not necessarily increase cardiovascular risk.

Several other studies have explored whether similar patterns apply to brain health, but the results are mixed.

Evidence overall suggests that studies conducted in Asian populations are more likely to report benefits of dairy consumption for cognitive health (the ability to think, remember and reason), while many European studies do not.

One possible explanation is that average dairy intake tends to be much lower in Asian countries, meaning modest consumption may have different effects than higher intakes.

For example, one Japanese study reported a reduced dementia risk among people who ate cheese, but overall consumption levels were very low and the research was sponsored by a cheese producer.

In contrast, another Japanese study funded by government grants found no protective effect of cheese.

Some long-term European studies have also reported benefits.

In a Finnish study of 2,497 middle-aged men followed for 22 years, cheese was the only food associated with a lower dementia risk, reduced by 28 per cent.

Other dietary factors also appear to matter.

Higher consumption of milk and processed red meat was associated with worse performance on cognitive tests, while fish intake was linked to better results.

A large study in the UK that followed nearly 250,000 people found lower dementia risk among those who ate fish two to four times a week, fruit daily and cheese once a week.

However, these studies have important limitations.

What people eat is usually self-reported, and changes in memory can affect both eating habits and how accurately people remember what they have eaten. To deal with this, the Swedish researchers took two extra steps.

First, they excluded anyone who already had dementia when the study began.

Then they repeated the same calculations after removing people who went on to develop dementia within the first ten years of the study.

This did not mean starting the study again or recruiting new participants. It simply meant re-checking the results using a smaller group of people who remained dementia-free for longer.

The reason for doing this is that the early stages of dementia can subtly change behaviour long before diagnosis.

People may eat differently, lose appetite or struggle to recall their usual diet. By focusing on participants who stayed cognitively healthy for many years, the researchers reduced the chance that these early changes were influencing the results.

Another important question is whether substitution played a role.

Some of the apparent benefits may reflect replacing red or processed meat with cheese or cream, rather than an effect of dairy itself.

Supporting this idea, the Swedish study found no association between full-fat dairy and dementia risk among participants whose diets remained stable over five years.

Most importantly, foods should not be considered in isolation.

Dietary patterns matter more than individual ingredients. Diets such as the Mediterranean diet, which is consistently associated with lower risks of both dementia and heart disease, include cheese alongside vegetables, fish, whole grains and fruit.

In the Swedish study, people who consumed more full-fat cheese and cream were also more educated, less likely to be overweight and had lower rates of conditions linked to dementia, including heart disease, stroke, high blood pressure and diabetes.

All of these factors independently reduce dementia risk.

This suggests that higher cheese intake tended to occur within healthier overall lifestyles, rather than alongside excess calorie consumption or poor metabolic health.

Overall, the evidence does not support the idea that full-fat dairy causes dementia, nor that fermented milk products reliably protect against it.

Full-fat cheese contains several nutrients relevant to brain health, including fat-soluble vitamins A, D and K2, as well as vitamin B12, folate, iodine, zinc and selenium.

These nutrients play roles in neurological function and may help support cognitive health.

That said, the data do not justify eating large amounts of cheese or cream as protective foods against dementia or heart disease.

The most consistent message remains that balanced diets, moderation and overall lifestyle matter far more than any single item on the cheese board.

Continue Reading

News

New obesity and diabetes drug set for Boots clinical trial

Published

on

Boots will run an obesity drug trial for a new type 2 diabetes medicine at selected stores in England, the chain has revealed.

Boots has partnered with Civia Health to set up clinical research sites at four stores in Nottingham, Brighton, Peterborough and Birmingham, connecting communities to local research opportunities for obesity, diabetes and cardiovascular conditions.

Marc Donovan is director of healthcare development at Boots.

He said: “Clinical research plays a vital role in the development of new treatments and therapies, and we are proud to support increased clinical research participation to drive better health outcomes for all.”

The company said this is the first time dedicated clinical research units have been set up in high street pharmacies, enabling people to take part in convenient locations.

Boots said the first study to be conducted by Civia Health at its stores is a Phase 3 trial, a late-stage study that tests safety and effectiveness before approval, focused on a new obesity and type 2 diabetes medicine.

Customers at Boots stores will be able to join Civia Health’s longitudinal health registry, Thrive, which tracks participants’ health over time, and access free health screenings.

The screenings will include measurements such as height, weight, blood pressure and blood tests to help people understand their health and identify studies for which they may be eligible.

Civia will deploy its clinical teams, technology and operational standards to the participating Boots stores to screen and enrol participants, bringing research capability to the high street and providing convenient locations for study appointments.

As part of the partnership, Boots will also provide details of research opportunities to its customers to support recruitment.

Mark Campbell, chief executive of Civia Health, said: “For too long, clinical research sites have been in out-of-town and hard-to-find locations that can feel unfamiliar.

“Instead of relying on the small number of people who actively seek out studies, we’re bringing research to a broader, more diverse group – people who might benefit but would never have found us otherwise.”

Continue Reading

Trending

Agetech World